Arca Biopharma slows losses, R&D expenses in Q2
BOULDER — Arca Biopharma Inc. (Nasdaq: ABIO) saw its losses for the second quarter of 2022 shrink by 33%, to $3.2 million from a $4.8 million net loss in the second quarter of 2021. That’s according to the quarterly report released by the drug manufacturer Wednesday.
Arca also more than halved its research and development expenses year-over-year, to $1.4 million from $3.5 million.
This comes as the company is exploring a merger or sale of assets; it established a committee to weigh these options amid a 2021 that saw it double its year-over-year losses.
Arca has two drugs in its pipeline: COVID-19 drug candidate rNAPc2 and Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that could be a potential treatment for atrial fibrillation in heart-failure patients.
Arca does not have a timeline for a merger or sale.
The company ended the quarter with $46.4 million in cash and equivalents on hand, enough to sustain its operations through the 2023 fiscal year.
BOULDER — Arca Biopharma Inc. (Nasdaq: ABIO) saw its losses for the second quarter of 2022 shrink by 33%, to $3.2 million from a $4.8 million net loss in the second quarter of 2021. That’s according to the quarterly report released by the drug manufacturer Wednesday.
Arca also more than halved its research and development expenses year-over-year, to $1.4 million from $3.5 million.
This comes as the company is exploring a merger or sale of assets; it established a committee to weigh these options amid a 2021 that saw it double its year-over-year losses.
Arca has two drugs in its pipeline: COVID-19 drug…
Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!
Online access PLUS print versions of all Bizwest publications
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
- 1-year access to daily email newsletter & breaking news alerts.
Online access for one year.
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year access to daily email newsletter & breaking news alerts.
Online and print versions of all Bizwest publications PLUS premium access to BizWest Datastore for one year.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to unlimited downloads from the BizWest Datastore!
- 1-year premium online access to the Breaking Ground website!
- 1-year access to daily email newsletter & breaking news alerts.
Premium access to the BreakingGround site plus online and print versions of all BizWest publications.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to the Breaking Ground website!
- 1-year access to daily email newsletter & breaking news alerts.
Premium access to the BreakingGround site plus online and print versions of all BizWest publications.
One month subscription includes:
- 1-year premium online access to the Breaking Ground website!
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
- 1-year access to daily email newsletter & breaking news alerts.